GlassScriptPhysician profile
Sydney Ain
NPI 1043062268
$1,694.63
in general payments reported to CMS, 2019-2025
17 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $500 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.24 |
| Education | $167.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.57 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $341.11 | 2024-2025 | Farxiga |
| Calliditas Therapeutics US INC. | $159.29 | 2024-2025 | Tarpeyo |
| Idorsia Pharmaceuticals US INC | $137.82 | 2025 | Tryvio |
| Amgen INC. | $112.79 | 2025 | Repatha |
| Alexion Pharmaceuticals, INC. | $96.82 | 2024 | Soliris, Ultomiris |
| Opko Pharmaceuticals, LLC | $91.40 | 2025 | Rayaldee |
| Lilly USA, LLC | $78.04 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $71.20 | 2025 | |
| Baxter Healthcare | $63.38 | 2024 | Renal - Pd |
| Apellis Pharmaceuticals, INC. | $43.90 | 2025 | Empaveli |
| Vantive US Healthcare LLC | $34.60 | 2025 | Renal - Pd |
| Merck Sharp & Dohme LLC | $30.56 | 2025 | Prevymis |
| Mallinckrodt Hospital Products INC. | $28.09 | 2024 | Acthar |
| Recordati_rare_diseases_inc. | $22.21 | 2025 | Cystadrops |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $22.21 | 2025 | |
| Corcept Therapeutics | $18.64 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Ain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.